BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 19, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Sep. 22, 2009
View Archived Issues
Nektar Coffers Brimming with Cash Thanks to $1.5B Deal
Nektar Therapeutics Inc. will end the year flush with cash, after entering a deal valued at $1.5 billion with AstraZeneca plc. to develop a late-stage bowel drug candidate and a preclinical pain product. (BioWorld Today)
Read More
Icagen, Pfizer Extend Deal; $1B in Milestones Still up for Grabs
Read More
BioCryst Gets More U.S. Funds for Peramivir, But Small Order
Read More
Good to the Bone: Denosumab Shines Again in Phase III Data
Read More
Analyst: Facet Investors Won't Bite on Biogen's Hostile Offer
Read More
1 H1N1 Shot Enough for Older Kids, But 2 Needed for Youngest
Read More
Other News To Note
Read More
Clinic Roundup
Read More
Financings Roundup
Read More